JPRN-UMIN000006793招募中2 期
Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer - Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer
ippon Medical School Musashikosugi Hospital0 个研究点目标入组 40 人开始时间: 2011年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of severe allergy 2) Simultaneous or metachronous double cancers 3) active infectious disease, 4) Severe comorbidity 5) Massive pleural effusion or ascites 6) Wattery diarrhea 7) Paralytic or mechanical bowel obstruction 8) Symptomatic brain metastasis 9) Patients who is receiving Fluorocytosine or Atazanavir Sulfate 10) Pregnant or lactating women or women of childbearing potential. 11) Amalgamation of mental disease or psychotic manifestation 12) Patients who are inadequate by investigator's decision.
研究者
相似试验
已完成
2 期
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
已完成
2 期
Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancerResistant ovarian cancerJPRN-UMIN000007318Kyorin University, School of Medicine20
已完成
2 期
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with metastatic gastric cancerElderly patients with metastatic gastric cancerJPRN-UMIN000009349ational Cancer Center Hospital40
已完成
2 期
Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)Colorectal cancerJPRN-UMIN000012063Kurume University Medical Center30
已完成
2 期
Multi-center, phase II study for combination therapy with weekly pacritaxel and 5'-DFUR in patients with unresectable or recurrent gastric cancerAdvanced or recurrent gastric cancerJPRN-UMIN000008631Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine45